Cat. No. 2192
Chemical Name: 4-(1H)-Quinazolinone
Biological ActivityInhibitor of poly(ADP-ribose) polymerase (PARP) (IC50 = 9.5 μM); displays mixed inhibition with respect to NAD+. Protective against ischemia-reperfusion induced ROS production, and subsequent mitochondrial and cell damage in rat heart. Anti-inflammatory in LPS-induced endotoxic mice in vivo; decreases NF-κB and AP-1 activation.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Veres et al (2004) Regulation of kinase cascades and transcription factors by a poly(ADP-ribose) polymerase-1 inhibitor, 4-hydroxyquinazoline, in lipopolysaccharide-induced inflammation in mice. J.Pharmacol.Exp.Ther. 310 247. PMID: 14999056.
Halmosi et al (2001) Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system. Mol.Pharmacol. 59 1497. PMID: 11353811.
Banasik et al (1992) Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J.Biol.Chem. 267 1569. PMID: 1530940.
If you know of a relevant reference for 4-HQN please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses 4-HQN from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: 4-HQN, supplier, PARP, inhibitors, inhibits, PolyADP-ribose, Polymerase, Polymerases, Tocris Bioscience, Poly(ADP-Ribose) Polymerase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent PARP inhibitor; orally bioavailableEntecavir
Potent and selective hepatitis B virus inhibitor
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.